MRSA Antibody Therapeutic Simultaneously Treats and Vaccinates Against Reinfection

Inventor(s): Olaf Schneewind Andrea DeDent Carla Emolo Dominique Missiakas Hwan Kim

    SUMMARY

    Staphylococcus aureus infections can recur without eliciting protective immunity due to Protein A (SpA), which contributes to the bacteria’s immune evasion tactics. This immune evasion is largely responsible for the threatening nature of the bacteria to human health.

    •The inventors developed and fully humanized a monoclonal antibody against the highly conserved S. aureus envelope protein, SpA.

    •The invention is a monoclonal antibody that neutralizes SpA activity on S. aureus to treat antibiotic resistant infections and prevent infection recurrence.

    •In in vitro proof-of-concept experiments with mouse and human blood, the antibody promoted opsonophagocytic killing of MRSA. In in vivo mouse models of staphylococcal disease, the antibody stimulated pathogen specific immune responses and protected against recurrent infection.

     

    FIGURE

    A)  Experimental design: passively immunized neonatal mice were subcutaneously challenged with MRSA, survivors were bled for serum analysis, and survivors were IV challenged with MRSA; (B) Treatment efficacy: the antibody improved survival following subcutaneous challenge; (C)  Blood serum analysis characterized the robust immune response following treatment + initial infection; (D) Vaccine efficacy: the protective immune response improved survival following intravenous challenge.

     

    ADVANTAGES

    ADVANTAGES

    •Reduces disease severity

    •Vaccinates against future infection

    •Works on multiple S. aureus strains

    •No toxicity

    •Does not promote antibiotic resistance

     

    APPLICATIONS

    •Simultaneous MRSA treatment and vaccine

    •Research tool

     

    PUBLICATIONS

    •Kim, H; et al. Protein A-specific monoclonal antibodies and prevention of Staphylococcus aureus disease in mice. Infect Immun. 2012 Oct; 80(10):3460-70.

    •Thammavongasa, V; et al. Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus. Vaccine. 2015 Jan 15;33(4): 523-6.

     

     

     

    • US: 9,556,281

    TECH DETAILS

    Published
    7/23/2019

    Reference ID
    11-T-092

    Have Questions?

    Michael Hinton

    Contact Michael Hinton, Manager of Market Intelligence, who can provide more detail about this technology, discuss the licensing process, and connect you with the inventor.

    This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of products and services, assist with our promotional and marketing efforts.

    Accept